信息披露事务管理制度 第一章 总 则 第一条 为规范青岛海尔生物医疗股份有限公司（以下简称"公司"）的信息披露行 为，正确履行信息披露义务，切实保护公司、股东、债权人及其他利益相关者的合法权 益，根据《中华人民共和国公司法》、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、 《上市公司信息披露管理办法》和《科创板上市公司自律监管指南第3号——日常信息披 露》等有关规定，结合《青岛海尔生物医疗股份有限公司章程》（以下简称"《公司章 程》"），制订本制度。 第二条 本制度适用于以下人员和机构： （一）公司董事和董事会； （二）公司董事会秘书和证券部； （三）公司高级管理人员； （四）公司各部门以及各子公司、分公司的负责人； 青岛海尔生物医疗股份有限公司 （五）公司控股股东和持有公司5%以上股份的股东； （六）其他依法负有信息披露职责的人员和机构。 第三条 本制度由公司董事会制订。董事会应当负责并保证本制度的有效实施，确保 公司相关信息披露的及时性和公平性，以及信息披露内容的真实、准确、完整。 公司证券部是董事会领导下负责公司信息披露事务的常设 ...

海尔生物公告，第三季度营收为5.66亿元，同比增长1.24%；净利润为5565.17万元，同比下降25.60%。 前三季度营收为17.61亿元，同比下降1.17%；净利润为1.98亿元，同比下降35.83%。 ...

Core Viewpoint - The article discusses the importance and development factors of platelet constant temperature oscillating storage boxes, highlighting their role in ensuring the safety and effectiveness of clinical blood transfusions through advanced temperature control and oscillation technology [2][4]. Group 1: Definition and Importance - Platelet constant temperature oscillating storage boxes are medical devices that maintain a stable temperature environment to preserve platelet activity, ensuring safe and effective blood transfusions [2]. - These devices prevent platelet aggregation and sedimentation, maintaining uniform distribution and functional integrity, and are equipped with temperature sensors and alarm systems for real-time monitoring [2]. Group 2: Development Factors - The growth of platelet constant temperature oscillating storage boxes is driven by factors such as aging population, improved medical standards, increased surgical procedures, regulatory requirements, public health emergencies, and technological integration [4]. - The aging population, particularly in emerging economies like China, is leading to a rigid increase in clinical blood demand, especially for platelet transfusions during surgeries [5]. Group 3: Quality and Safety Requirements - Advances in medical technology have raised the performance requirements for storage boxes, necessitating precise temperature control and oscillation parameters to accommodate new storage solutions [7][8]. - The emphasis on green healthcare has led to the adoption of low-power motors and environmentally friendly refrigerants, enhancing sustainability and user-friendliness [8]. Group 4: Regulatory and Public Health Considerations - Stricter regulations on blood product management are pushing the development of high-precision and reliable storage boxes, requiring compliance with quality management standards [9]. - The COVID-19 pandemic highlighted vulnerabilities in the blood supply chain, prompting the need for larger, intelligent storage solutions to ensure adequate platelet reserves during emergencies [10]. Group 5: Future Trends - The future of platelet constant temperature oscillating storage boxes is expected to focus on smart and digital transformation, with over 70% of market products projected to integrate AI-driven predictive maintenance and real-time data analysis by 2027 [11]. - There is a strategic shift towards integrated solutions that encompass the entire blood management process, with expectations that this model will account for over 60% of market share by 2028 [12]. - The market for portable storage boxes is anticipated to grow significantly, driven by the increasing demand for emergency medical services and mobile blood banks [13]. Group 6: Industry Leaders - Qingdao Haier Biomedical is a leader in the field, providing innovative digital solutions for blood safety management, with a reported annual revenue of 2.284 billion yuan in 2024 [15]. - Haier's platelet constant temperature oscillating storage boxes are designed to meet stringent storage requirements, integrating IoT technology for enhanced monitoring and data traceability [15][16].

Core Points - The company will hold an investor briefing on October 31, 2025, to discuss its Q3 2025 financial results and operational performance [2][3][4] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][5] - Investors can submit questions from October 24 to October 30, 2025, and the company will address common concerns during the briefing [2][4][6] Meeting Details - The investor briefing is scheduled for October 31, 2025, from 11:00 AM to 12:00 PM [2][5] - The location for the meeting is the Shanghai Stock Exchange Roadshow Center, accessible via the website [2][5] - Participants can join the meeting online and will have the opportunity to ask questions [4][5] Contact Information - For inquiries, investors can contact the Haier Biomedical Securities Department at phone number 0532-88935566 or via email at haierbiomedical@haierbiomedical.com [6]

证券代码：688139 证券简称：海尔生物 公告编号：2025-048 青岛海尔生物医疗股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 会议召开时间：2025 年 10 月 31 日(星期五)上午 11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址： 二、 说明会召开的时间、地点 （一） 会议召开时间：2025 年 10 月 31 日 （星期五） 11:00-12:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 24 日（星期五）至 10 月 30 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 haierbiomedical@haierbiomedical.com 进行提问。公司将在说明会上对投资者 普遍关注的问题 ...

Core Viewpoint - Haier Biomedical's major shareholder, Qingdao Guoxin Financial Holdings Co., Ltd., has increased its stake, reflecting confidence in the future of the life sciences industry and recognition of Haier Biomedical's governance, industry position, business capabilities, operational results, and risk management [1] Group 1: Shareholder Information - The controlling shareholder of the increased stake is Qingdao Guoxin Financial Holdings Co., Ltd., with actual control by the State-owned Assets Supervision and Administration Commission of the Qingdao Municipal People's Government [1] - The investment is based on the shareholder's long-term positive outlook on the life sciences sector and the company's performance [1] Group 2: Future Plans and Strategies - Haier Biomedical aims to deepen its focus on four major industries and enhance the integration of AI technology with life sciences and medical innovation scenarios [1] - The company plans to accelerate its globalization process to provide returns to investors [1]

Core Viewpoint - Haier Biomedical has received a report from Qindao Jiushi Investment Management Co., indicating that Jiushi Youxuan No. 1 Fund plans to increase its stake in the company by 15,897,909 shares, representing 5.00% of the total share capital, due to a long-term positive outlook on the life sciences industry and recognition of Haier Biomedical's performance in governance, industry position, business capabilities, operational results, and risk management [1][2]. Group 1 - Jiushi Youxuan No. 1 Fund is currently the second-largest circulating shareholder of Yinkang Life, showcasing its strategic focus on the medical technology sector and recognition of Haier Biomedical's solid fundamentals and clear growth logic [2]. - Haier Biomedical, a leader in low-temperature storage equipment in the biomedical sector, achieved a net profit of 143 million yuan in the first half of 2025, with new industry revenue accounting for 47% of total revenue, driving performance growth [2]. - The company has established a collaborative development framework across four major industries: low-temperature storage, smart medication, blood technology, and laboratory solutions, with significant market shares in various segments [2]. Group 2 - Haier Group, the actual controller of Haier Biomedical, has recently formed a comprehensive strategic partnership with Ant Group to promote the digital upgrade of healthcare services, positioning Haier Biomedical for new growth opportunities [3]. - The investment from Jiushi Youxuan No. 1 Fund is seen as a recognition of Haier Biomedical's technological barriers and growth potential, which may boost investor confidence and provide stronger momentum for the company's long-term development [3].

Core Viewpoint - The announcement details that Qingdao Jiushi Investment Management Co., Ltd. has increased its stake in Haier Biomedical to 5% without triggering a mandatory takeover bid [2][3]. Group 1: Shareholding Changes - Jiushi Youxuan No. 1 Private Securities Investment Fund acquired 15,897,909 shares of Haier Biomedical from August 14, 2024, to October 14, 2025, representing 5% of the total share capital [4][10]. - The increase in shareholding does not change the company's controlling shareholder or actual controller [3][5]. Group 2: Investment Rationale - The investment is based on confidence in the future development of the life sciences industry and recognition of Haier Biomedical's governance, industry position, business capabilities, operational results, and risk management [10]. - Jiushi Youxuan No. 1 has no current plans to increase or decrease its stake in the next 12 months [11]. Group 3: Compliance and Reporting - The report complies with relevant laws and regulations, including the Securities Law and the Management Measures for the Acquisition of Listed Companies [7][12]. - The report confirms that the information disclosed is accurate and complete, with no misleading statements or omissions [12].

Core Viewpoint - Haier Biomedical has been targeted for a stake acquisition by Jiushi Investment, reaching a 5% shareholding threshold, indicating confidence in the company's future development and potential for collaborative growth [1][4][2]. Group 1: Investment Details - Jiushi Investment's Jiushi Preferred No. 1 Fund acquired 15,897,900 shares of Haier Biomedical, representing 5% of the total share capital [4]. - The investment was made through secondary market transactions and was funded by Jiushi Investment's own capital [4]. - Jiushi Investment has no immediate plans to increase or decrease its stake in Haier Biomedical within the next 12 months [4]. Group 2: Company Background - Haier Biomedical is a subsidiary of Haier Group's health ecosystem brand, established in October 2005 and listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in October 2019 [7]. - The company has faced a continuous decline in stock price over the past four years, with significant drops of 29.83%, 35.46%, 12%, and 6.38% in the years 2022, 2023, 2024, and 2025 respectively [10]. Group 3: Financial Performance - In the first half of 2025, Haier Biomedical reported revenue of 1.196 billion yuan, a decrease of 2.27% year-on-year, and a net profit of 143 million yuan, down 39.09% year-on-year [8]. - The company attributes the profit decline to external factors, new capacity ramp-up, and strategic investments, but anticipates improvement as industry conditions recover [8]. - The overseas business showed strong growth, with revenue of 427 million yuan, a year-on-year increase of 30.17%, achieving the highest quarterly revenue and growth rate since 2023 in the second quarter [9].

Core Viewpoint - The report outlines the equity change of Qingdao Haier Biomedical Co., Ltd. (referred to as "Haier Biomedical") due to an increase in shareholding by Qingdao Jiushi Investment Management Co., Ltd. through its fund Jiushi Preferred No. 1, which acquired 15,897,909 shares, representing 5% of the total share capital of the company, from August 14, 2024, to October 14, 2025 [8][15]. Group 1: Information Disclosure Obligations - The information disclosure obligations are based on the Securities Law of the People's Republic of China and related regulations, ensuring that the report covers all changes in shareholding [1]. - The information disclosure obligor confirms that the report does not contain any false records, misleading statements, or significant omissions, and assumes legal responsibility for its authenticity and completeness [2]. Group 2: Purpose and Future Plans of Equity Change - The purpose of the equity change is driven by a long-term positive outlook on the life sciences industry and recognition of Haier Biomedical's performance in governance, industry position, business capabilities, operational results, and risk management [5]. - There are currently no explicit plans or agreements for increasing or decreasing shareholding in the next 12 months, and any future changes will be disclosed in accordance with relevant laws and regulations [7]. Group 3: Details of Equity Change - From August 14, 2024, to October 14, 2025, Jiushi Preferred No. 1 increased its shareholding in Haier Biomedical by 15,897,909 shares, funded by its own capital [8]. - Following this equity change, Jiushi Preferred No. 1 has become a shareholder holding more than 5% of the company's shares [9]. Group 4: Impact on Company Control - The equity change will not alter the controlling shareholder or actual controller of Haier Biomedical [16].